Humacyte has received FDA acceptance of its Investigational New Drug application for a first-in-human study of its coronary tissue-engineered vessel, or CTEV, in coronary artery bypass grafting.
The company plans to begin a Phase 2a study during the third quarter of 2026. The trial will enroll ten adults with coronary artery disease and evaluate the CTEV as a conduit during bypass surgery. Patency will be assessed two months after implantation, with participants followed for as long as three years.
The CTEV is a small-diameter, bioengineered human blood vessel designed to be stored and available off the shelf. It is manufactured using the same underlying system as Humacyte’s larger-diameter acellular tissue-engineered vessel, which is sold as Symvess for certain extremity vascular-trauma procedures.
Humacyte’s vessels are manufactured from human vascular cells that produce an extracellular-matrix tube. The cells are subsequently removed, leaving an acellular structure designed to avoid immune rejection and become repopulated with the recipient’s own cells following implantation.
The company reports that the coronary vessel has been evaluated in pig, sheep and baboon bypass models. In a six-month baboon study, the vessels remained patent, became populated with endothelial and smooth-muscle cells and remodeled in response to the animals’ coronary anatomy.
The business significance
Coronary bypass represents a considerably larger opportunity than emergency vascular trauma.
More than 400,000 coronary grafts are implanted annually in the United States. Current bypass procedures rely primarily on vessels harvested from the patient, including the internal mammary artery, radial artery and saphenous vein. Vein harvesting adds operating time and can cause wound complications, while some patients lack suitable vessels for bypass.
An off-the-shelf coronary vessel could eliminate the need to harvest an additional vessel and provide surgeons with a standardized conduit when patient anatomy or vessel quality is inadequate. However, small-diameter vascular grafts face demanding biological and mechanical requirements. They must resist thrombosis, remain patent under coronary flow and remodel without developing stenosis, aneurysm or structural failure.
From a platform perspective, the CTEV demonstrates the potential leverage of Humacyte’s manufacturing infrastructure. The company is attempting to use one tissue-engineering platform across vascular trauma, dialysis access, peripheral arterial disease, coronary bypass and other tissue applications. Success in multiple indications could spread manufacturing and quality-system costs across a broader product portfolio.
FDA acceptance of an IND is permission to begin clinical testing; it is not evidence that the product is effective, nor does it represent marketing approval. A ten-patient trial will primarily provide an initial assessment of safety, technical feasibility and early patency.
Nevertheless, entering human coronary testing is a significant step for the biofabrication industry. It moves tissue-engineered blood vessels from specialized vascular applications toward one of cardiovascular surgery’s largest and most clinically important markets.
Find original article here.
Leave a comment